Locally grown materials, architecture and other design elements caused seven judges to choose the University of Maine Student Recreation and Fitness Center for the 2008 Athletic Business Facility Magazine award on Dec. 5. The award is given annually to new buildings throughout the United States and Canada.
The Rec Center, designed by Cannon Design of Boston, was one of 10 winning buildings that “demonstrate sound design principles in the areas of Read the rest of this entry »

Thursday, January 15, 2009
French Hospital is honored for excellence in three different areas of service.
The hospital received awards for its excellence in patient service, cardiovascular care and growth and expansion.
Catholic Healthcare West owns the hospital. Its CEO has ties to President-Elect Barack Obama and has worked with him in Chicago on several occasions.
Catholic Healthcare West CEO Lloyd Dean said he is excited about what the Read the rest of this entry »

KING OF PRUSSIA, Pa.
,
Jan. 5
/PRNewswire/ — Prism Pharmaceuticals
announced today that the U.S. Food & Drug Administration (FDA) has approved
the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a
novel, patent-protected, cosolvent free formulation of the antiarrhythmic
agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone(R)
Intravenous. NEXTERONE is indicated for the treatment and prophylaxis Read the rest of this entry »

RQE.L
), the UK company developing treatments based on
the use of stem cells, surge 32.4 percent as the U.S. FDA gives Geron Corp
(
GERN.O
) clearance to begin the world’s first human clinical trial of embryonic
stem cell-based therapy.
“This is good news for ReNeuron, as its ReN001 therapy (derived from
similarly controversial foetal cells) is currently on clinical hold in the U.S,”
Daniel Stewart says in a note.
“It is possible that further Read the rest of this entry »

(RTTNews) - 
Thursday, Columbia-based stem cell therapeutic company, Osiris Therapeutics Inc. (OSIR:
), said that it has received clearance from the U.S. Food and Drug Administration, or FDA, to broaden its expanded access program for Prochymal, thereby making the investigational stem cell product available to adults with life-threatening Graft vs. Host Disease or GvHD.
Prochymal is currently in its Phase Read the rest of this entry »

Many people know that the Federal Reserve sets interest rates in order to loan money to other banks so they can keep cash
flowing throughout the U.S. financial system. Mostly, this works great for everyone involved. But, sometimes, banks and thrifts
need a little extra cash, mostly so they can meet the reserve requirement (the minimum amount of deposits banks need to be
considered in good financial shape).
Read the rest of this entry »

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the
Company has received a complete response letter from the U.S. Food and
Drug Administration (FDA) for its New Drug Application (NDA) for
balsalazide tablet studied as a treatment of mild-to-moderate active
ulcerative colitis in patients 18 years and older. Based on its review,
the FDA has determined that the application cannot be approved in its
present form and that clinical data from Read the rest of this entry »

OPKO Health, Inc. (NYSE Alternext US:OPK) today announced that it has
received 510(k) clearance from the U.S. Food and Drug Administration
(“FDA”) to begin marketing in the United States its Spectral OCT SLO
Combination Imaging System. Currently marketed internationally by the
Company’s subsidiary, OPKO Instrumentation, LLC, the Spectral OCT SLO is
the product of more than a decade of innovation in the field of
combination imaging. High-resolution Read the rest of this entry »

Cost basis is the cost at which you entered a position or purchased an asset. It is the total price you paid for, say,
your house, a stock, mutual fund, etc…–and by total we mean including all commissions, accrued interests and other expenses.
Cost basis is used to determine tax liabilities.
For example, if you bought 100 shares of IBM at $111.45, and IBM is
now worth $120 a share, the current value Read the rest of this entry »

VANCOUVER, BRITISH COLUMBIA –
Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that one of the company’s collaborators, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), has received clearance from the U.S. Food and Drug Administration (FDA) to begin enrolling patients in a clinical trial for ALN-VSP, a product developed with Tekmira’s SNALP delivery technology.
Mark J. Murray, Tekmira’s President and CEO, said, “We are pleased that ALN-VSP, Read the rest of this entry »